CT1182 Injection, Phase 1, Relapsed Non Hodgkin Lymphoma
Summary
The NIH has registered a new early Phase 1 clinical trial (NCT07548697) on ClinicalTrials.gov to evaluate the safety, efficacy, metabolic kinetics, and pharmacodynamics of CT1182 injection in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The single-arm, open-label study targets r/r B-NHL subtypes including DLBCL and Follicular Lymphoma. This is a prospective patient enrollment record; no compliance obligations or regulatory actions are imposed.
“This study is a single arm, open label, dose exploring clinical study to evaluate the safety, efficacy, metabolic kinetics and pharmacodynamics of CT1182 cells in patients with relapsed / refractory B-cell non Hodgkin lymphoma (r/r B-NHL).”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
The NIH has added a new clinical trial registration (NCT07548697) to ClinicalTrials.gov describing a Phase 1 dose-exploration study of CT1182 injection for relapsed/refractory B-cell non-Hodgkin lymphoma, including DLBCL and Follicular Lymphoma subtypes. The trial will assess safety, efficacy, metabolic kinetics, and pharmacodynamics. This is an informational registry entry with no binding compliance requirements. Clinical investigators, oncology trial sponsors, and hematology/oncology providers should note the trial as a potential enrollment option for eligible patients.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
Early Phase 1 NCT07548697 Kind: EARLY_PHASE1 Apr 23, 2026
Abstract
This study is a single arm, open label, dose exploring clinical study to evaluate the safety, efficacy, metabolic kinetics and pharmacodynamics of CT1182 cells in patients with relapsed / refractory B-cell non Hodgkin lymphoma (r/r B-NHL).
Conditions: B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL)
Interventions: CT1182 injection
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.